Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination.
Clinical success in tumor vaccination frequently does not reach expectation. Since vaccination protocols are quite variable, we used the murine renal cell carcinoma line RENCA transfected with the lacZ gene (RENCA-beta-gal) to compare the efficacy of two different vaccination strategies or their combination and to elaborate on the underlying mechanisms. BALB/c mice were vaccinated either with naked lacZ DNA or with attenuated Salmonella typhimurium transformed with lacZ DNA or with dendritic cells (DC) loaded with the beta-galactosidase protein or mice were vaccinated with both DNA and protein. Although all regimens led to a prolongation of survival time, oral vaccination with transfected S. typhimurium followed by i.v. transfer of protein-loaded DC provided the optimal schedule. In this setting, >50% of mice remained tumor free after challenge with 10 times the lethal tumor dose of RENCA-beta-gal. As explored in transfer experiments, the superior efficacy of combining DNA and protein vaccination is due to the facts that 1) optimal protection depends on both activated CD4(+) and CD8(+) cells and 2) CD8(+) CTL are most strongly activated by vaccination with transformed Salmonella, whereas vaccination with protein-loaded DC is superior for the activation of Th. The latter induced sustained activation of CTL and recruitment of nonadaptive defense mechanisms. The data demonstrate the strength of DNA vaccination, particularly by the oral route, and provide evidence that a combined treatment with protein-loaded DC can significantly increase the therapeutic efficacy.
Zöller
M
M
Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany. m.zoeller@dkfz.de
Christ
O
O
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D002455:Cell Division / Q000235:genetics / Q000276:immunology; D004269:DNA, Bacterial / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D003713:Dendritic Cells / Q000201:enzymology / Q000276:immunology / Q000637:transplantation; D004357:Drug Synergism; D007113:Immunity, Innate / Q000235:genetics; D007279:Injections, Subcutaneous; D007680:Kidney Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D007763:Lac Operon / Q000276:immunology; D008213:Lymphocyte Activation / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D011506:Proteins / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D012486:Salmonella typhimurium / Q000235:genetics / Q000276:immunology; D015996:Survival Rate; D014170:Transformation, Genetic; D014407:Tumor Cells, Cultured; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D001616:beta-Galactosidase / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D004269:DNA, Bacterial; D011506:Proteins; D019444:Vaccines, DNA; D001616:beta-Galactosidase